Home Alzheimer’s Disease Phase III KEYNOTE-177 Study of Pembrolizumab Doubles PFS in MSI-H/dMMR mCRC

Phase III KEYNOTE-177 Study of Pembrolizumab Doubles PFS in MSI-H/dMMR mCRC

The phase III KEYNOTE-177 study demonstrated that front-line therapy with the immune checkpoint inhibitor pembrolizumab (Keytruda) doubled progression-free survival (PFS) versus standard of care chemotherapy in patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC).1

The randomized, open-label, phase III trial, presented during a 2020 ASCO Virtual Scientific Program press briefing, is the first in which pembrolizumab has been shown to benefit these patients when used as a front-line therapy. 

“These long-awaited trial results will change clinical practice,” lead author Thierry André, MD, of the Sorbonne Université and Hôpital Saint Antoine in Paris, said in an ASCO-issued press release.2 “Pembrolizumab works in non-randomized studies in this group of patients with advanced disease. This randomized study…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

please help us fundraise (501c3 non-profit) : braincancer

I work with OurBrainBank, a start-up non-profit dedicated to moving glioblastoma from terminal to treatable, powered by patients.We're a registered 501c3 non-profit in the...

Cancer and Mental Health Re-post : braincancer

Hello!I would like to thank everyone who participated in my survey these past few months! I received a tremendous response and I truly, truly...

Recent Comments